Glucagon (22-29)

Glucagon (22-29) is partial agonist of Glucagon (19–29). Glucagon specifically inhibits the Ca2+ pump in liver plasma membranes independently of adenylate cyclase activation[1][2].

Signaling Pathways >> Others >> Others

Research Areas >> Metabolic Disease

Glucagon (22-29) produces only a 5-15% maximal inhibition of (Ca2+-Mg2+) ATPase, with a low potency (Ki=1 μM), similar to that of native glucagon[1]. Glucagon (22-29) (10 nM) evokes an early small decrease of cell contraction when added alone and an 18% significant positive inotropic effect when added in combination with 30 nM glucagon. Glucagon (22-29) thus appears to act as a partial agonist of miniglucagon[2]. Glucagon (22-29) consists of the COOH-terminal part of miniglucagon but lacks the three Ala1g-Gln20-Asp21 residues[2].